From Yahoo Finance: 2025-06-20 16:07:00

Incyte Corporation (NASDAQ:INCY) teams up with QIAGEN to boost blood cancer diagnostic solutions. The strategic partnership focuses on developing a novel diagnostic panel to support investigational treatments for myeloproliferative neoplasms (MPNs), specifically targeting mutant calreticulin (mutCALR) for myelofibrosis (MF) and essential thrombocythemia (ET). QIAGEN will develop a multimodal panel using next-generation sequencing (NGS) technology to identify key gene alterations in MPNs. Incyte is known for developing drugs for rare and hard-to-treat diseases, with a focus on oncology and inflammation/autoimmunity. Check out the 10 biotech stocks screaming a buy, including INCY.



Read more at Yahoo Finance: Incyte (INCY) Teams Up with QIAGEN to Boost Blood Cancer Diagnostic Solutions